



Digestive Diseases Research Seminar
Presented by Yale School of Medicine,
Department of Internal Medicine, and Section of Digestive Diseases

YaleCME
CONTINUING MEDICAL EDUCATION

New Advances in the Management of Patients with NASH

Rohit Loomba, MD, MHSc

Director, NAFLD Research Center; Director of Hepatology;
Professor of Medicine; Vice Chief, Division of Gastroenterology
University of California, San Diego

Tuesday, December 15, 2020

5:00 - 6:00 pm

<https://zoom.us/j/98915800684?pwd=eldMR3ZYaHZVUDk0eHJZQ016bUdDZz09>

Host: Silvia Vilarinho, MD, PhD

To record your attendance to this activity, text the Activity Code (20535) for your RSS activity to 203-442-9435.
You will receive a message back that verifies your activity attendance has been recorded for CME credit.

There is no corporate support for this activity. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **Target Audience:** YSM faculty, fellows, nurses, residents, medical students, staff, and other health care providers. **Designation Statement:** The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity. **Needs assessment:** Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in the US. Diagnosing patients who have progressive form of NAFLD called nonalcoholic steatohepatitis (NASH) is crucial as they have increased risk of cardiovascular disease (CVD) and hepatocellular carcinoma (HCC). While liver biopsy is considered as the gold standard, various non-invasive assessments have been developed to identify patients who are at risk. As such, there is a need to compare different modalities based on availability and accuracy. **Objectives:** Identify patients at increased risk for NASH; Incorporate into clinical practice the current standard of care for diagnosis, management and treatment of NAFLD/NASH; Describe recent evidence and recommendations regarding new and emerging diagnostic modalities for NASH; Describe the mechanisms of action of novel agents for the treatment of NASH; Discuss recent evidence regarding the safety and efficacy of new and emerging agents for the treatment of NASH. **Faculty Disclosures:** R Loomba – Consultant: Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Inipharma, Intercept, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Sagimet, 89 bio, and Viking Therapeutics. Grant PI: Allergan, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead, Intercept, Inventiva, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Pfizer and Siemens; S Vilarinho – None. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. **This course will fulfill the licensure requirement set forth by the State of Connecticut.**